Dr. Ramaprasad Srinivasan
Claim this profileNational Cancer Institute LAO
Studies Skin Cancer
Studies Renal Cell Carcinoma
2 reported clinical trials
5 drugs studied
Area of expertise
1Skin Cancer
Stage IV
FH positive
2Renal Cell Carcinoma
Stage IV
FH positive
Affiliated Hospitals
Clinical Trials Ramaprasad Srinivasan is currently running
Palbociclib + Sasanlimab
for Kidney Cancer
Background: Kidney cancer is the 12th leading cause of cancer-related death in the United States. Some kidney tumors do not respond well to current treatments. Better treatments are needed. Objective: To test a pair of drugs (sasanlimab and palbociclib) in people with kidney cancers. Eligibility: People aged 18 years and older with kidney cancer; specifically, clear cell renal cell carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC). Design: Participants will be screened. They will have a physical exam with blood tests. They will have an imaging scan and a test of their heart function. They may have a biopsy; that is, a sample of tissue will be cut from the tumor. Participants will be treated in 28-day cycles for up to 2 years. Palbociclib is a pill taken by mouth. Participants will take this drug once a day for 21 days during each 28-day treatment cycle. They will write down the dates and times they take these pills in a diary. Sasanlimab is an injection under the skin. Participants will receive this injection on the first day of each treatment cycle. Imaging scans and blood tests will be repeated throughout the treatment. Tumor biopsies may be repeated up to 3 times; these biopsies are optional. Participants will have follow-up visits every month for 3 months after treatment ends. They will continue to have imaging scans every 3 months; these scans may be done close to home. The results can be sent to researchers. Participants will remain in the study up to 6 years.
Recruiting1 award Phase 1 & 210 criteria
Triple Drug Therapy
for Kidney Cancer
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.
Recruiting1 award Phase 218 criteria
More about Ramaprasad Srinivasan
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ramaprasad Srinivasan has experience with
- Palbociclib
- Sasanlimab
- Atezolizumab
- Bevacizumab
- Erlotinib
Breakdown of trials Ramaprasad Srinivasan has run
Renal Cell Carcinoma
Kidney Tumors
Leiomyomatosis and Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ramaprasad Srinivasan specialize in?
Ramaprasad Srinivasan focuses on Skin Cancer and Renal Cell Carcinoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are FH positive.
Is Ramaprasad Srinivasan currently recruiting for clinical trials?
Yes, Ramaprasad Srinivasan is currently recruiting for 2 clinical trials in Bethesda Maryland. If you're interested in participating, you should apply.
Are there any treatments that Ramaprasad Srinivasan has studied deeply?
Yes, Ramaprasad Srinivasan has studied treatments such as Palbociclib, Sasanlimab, Atezolizumab.
What is the best way to schedule an appointment with Ramaprasad Srinivasan?
Apply for one of the trials that Ramaprasad Srinivasan is conducting.
What is the office address of Ramaprasad Srinivasan?
The office of Ramaprasad Srinivasan is located at: National Cancer Institute LAO, Bethesda, Maryland 20892 United States. This is the address for their practice at the National Cancer Institute LAO.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.